6. Ovid Therapeutics (NASDAQ:OVID)
Ovid Therapeutics takes the No. 6 position because its story is not built on hype alone. Trading around $2.73 with a market capitalization near $372 million, OVID is a small-cap biotech stock focused on serious neurological conditions, and its improved cash runway makes it more interesting this June. In a biotech market where many penny stocks are constantly fighting for survival, breathing room can be a major competitive advantage.
The company strengthened its balance sheet through a $60 million private placement, with expected runway into 2029. That is one of the biggest reasons OVID ranks this high. In biotech investing, cash runway can be just as important as a promising pipeline. A company may have excellent science, but if it cannot fund its trials or operations, shareholders are exposed to dilution risk. OVID’s improved runway gives it time to execute, develop its programs, and wait for the right value-creating milestones.
The focus on serious neurological conditions also gives OVID a compelling angle. Neurology is one of the hardest but potentially most valuable areas in healthcare. Disorders affecting the brain and nervous system often have limited treatment options, high unmet medical need, and complex development pathways. That combination makes neurological biotech stocks risky, but also highly attractive when companies show credible progress.
Compared with some names higher on this list, OVID does not have the same commercial strength. It is not yet in the same category as a company with a major revenue-generating approved product. But among sub-$3 biotech stocks, the balance-sheet improvement gives it a better foundation than many speculative peers. Investors searching for “biotech penny stocks with cash runway,” “neurology biotech stocks,” and “NASDAQ healthcare stocks under $5” may find OVID interesting because it has both a defined therapeutic focus and enough capital to keep advancing.
The risk is that cash alone does not create shareholder value. The company still needs clinical execution, strong data, and meaningful investor confidence. A long runway can protect the company from immediate dilution pressure, but the stock still needs catalysts to move higher. That is why OVID sits in the middle of the ranking. It has a better survival profile than many small-cap biotech names, but it still needs pipeline progress to prove that the market should re-rate the stock.
YOU MUST READ THIS:
Click here to continue reading and checkout the Top 5 Best Biotech Penny Stocks to Buy This June.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
